沙美特罗/氟替卡松联合孟鲁斯特钠治疗咳嗽变异型哮喘的疗效观察

Observation of effect of salmeterol /fluticasone combined with montelukast in the treatment of patients with cough variation asthma

目的观察沙美特罗/氟替卡松联合孟鲁斯特钠治疗咳嗽变异型哮喘(CVA)的疗效。方法收集我院门诊及住院的CVA患者96例,随机分为A、B、C组。A组给予吸入沙美特罗/氟替卡松粉入剂50μg/250μg早,晚各1次,同时给予孟鲁斯特钠10 mg口服,每天1次;B组给予孟鲁斯特钠10mg口服,每天1次;C组给予沙美特罗/氟替卡松粉入剂50μg/250μg吸入早、晚各一次。三组疗程均为8周。对比三组治疗前后的临床疗效及肺功能改变。结果三组治疗的临床疗效及肺功能均较治疗前有不同程度的改善(P<0.05);治疗后三组比较,A组的临床疗效及肺功能改善明显优于B、C两组(P<0.05),B组和C组临床疗效及肺功能改善相当,差异无统计学意义。结论沙美特罗/氟替卡松联合孟鲁斯特钠改善CVA的临床症状及肺功能明显,疗效更为显著。

Objective To observe the curative effect of salmeterol/fluticasone combined with montelukast in the treatment of patients with cough variation asthma.Methods 96 patients with cough variation asthma were randomly divided into three groups.The group A was given the inhalation of salmeterol/fluticasone （50ug/250ug） twice a day at morning and night.Besides,the group B was given montelukast 10 mg once a day.The group B was treated with montelukast orally 10mg once a day.The group C inhaled salmeterol/fluticasone （50ug/250ug） twice a day at morning and night.The total treatment course was 8 weeks.The effect and the lung function were estimated and compared among the three groups before and 8 weeks after the treatment.Results The effect and the lung function of the three groups were all improved after the treatment （P ＜ 0.05）,and the improvement of curative effect and lung function was more pronounced in the group A than in the rest two groups （P ＜ 0.05）.There was no obvious difference between the group B and the group C.Conclusion Salmeterol/fluticasone combined with montelukast can improve the pulmonary function and clinic symptom of CVA patients,and it has a better curative effect in the treatment of CVA patients.